



almacgroup.com

GET IN TOUCH

Global HQ
+44 28 3833 2200

US HQ
+1 215 660 8500

Asia HQ
+65 6309 0720

EU HQ
+353 42 932 0718

Durham, NC, USA
+1 (919) 479 8850

Japan
+81 367 218720

A unique
culture
delivering
exceptional
solutions



Welcome to Almac Group

A unique culture delivering exceptional solutions.

The Almac Group is an established contract development and manufacturing organisation that provides an extensive range of integrated services to the pharmaceutical and biotech sectors globally.

We are a private organisation, wholly owned by the McClay Foundation (see page 27), and have organically grown over the last 50 years, now employing over 5,600 highly skilled personnel.

At Almac, we are proud of our global reputation for excellence delivering expertise right across the drug development lifecycle and offering a tailored solution to each of our clients.

Our work is underpinned by a simple commitment to every client we partner with:

We will be exceptional, always.



Our Areas of Specialism

The Almac Group offers a highly specialised, personalised and expert service along each stage of the drug development lifecycle and beyond. Our innovative services range from R&D, biomarker discovery development and commercialisation through to product sales.

Our areas of specialism are:

- Drug Discovery
- Diagnostic Services
- API, Chemical Development & Analytical Services
- Pharmaceutical Development
- Clinical Services
- Clinical Technologies
- Commercial Services
- Product Sales, Marketing & Launch Services

Our unique combination of inspirational people, exceptional innovation and outstanding quality, enables us to work with you in the most appropriate manner for your situation: either on a single standalone project or on a longer term basis as your strategic partner.



Drug Discovery

A research driven drug discovery business dedicated to the development of novel and innovative approaches to the treatment of diseases of unmet need.

The Almac Discovery business model focuses on development of First-in-Class pre-clinical stage assets which are then licenced to pharmaceutical partners for further development.

We also seek to collaborate with partners to apply our medicinal chemistry and translational biology expertise to targets of mutual interest.

Key research themes include deubiquitinase enzymes and protein drug conjugates.




Diagnostic Services

We are a stratified medicine business specialising in biomarker driven clinical trials. Our diagnostic experience spans oncology, immunology, CNS and infective diseases.

Our global laboratories offer tailored solutions from discovery to commercialisation including biomarker discovery, custom assay development and validation, DNA and RNA panels, flexible CDx development and commercialisation models, expert regulatory support and bioinformatics and software development.

Our focus is on the discovery, development and commercialisation of diagnostic and CDx (companion diagnostic) tests. We also facilitate biomarker clinical trial management and clinical test delivery from our CLIA-accredited labs.



API, Chemical Development & Analytical Services

We provide integrated services from development to commercial scale of advanced intermediates and Active Pharmaceutical Ingredients (API).

Almac Sciences provides a range of services for small molecules, including highly potent and peptides. We have a proven track record of saving time and cost through the integration of our services and application of innovative biocatalysis and technology solutions.

We also offer a full suite of analytical testing for a range of different product types including small molecules, peptides, biologics, conjugates, potent and controlled substances. Our vast pool of scientific knowledge can help to overcome the analytical challenges that typically arise during drug development.



Pharmaceutical Development

Addressing the increasing pressure on pharmaceutical companies to bring clinical candidates through their pipeline faster and with greater efficiency, Almac Pharma Services provides expert pharmaceutical drug product development solutions.

Our scientists can develop clinical candidates into optimum formulations and manufacture solid oral dose products for all stages of clinical trials. From developing a fit-for-purpose formulation for First-in-Human trials, to scaling up for late phase trials.




Clinical Services

We have vast experience in providing an expanding array of best-in-class solutions to the global pharmaceutical and biotech industries.

Guided by our extensive clinical supply experience and expertise, Almac Clinical Services is recognised as an innovative, global solutions provider within the specialised and complex market of clinical trial supply.

Our integrated and adaptable solutions, offer the most flexible approach to support the delivery of global clinical trials from protocol right through to patient delivery.

Our core purpose is to be the partner of choice, to deliver the next generation of health care solutions effectively and to focus on winning for you and your patients.



Clinical Technologies

We help the biopharmaceutical industry bring new therapies to those in need by empowering trial sponsors to pro-actively manage sites, patients and clinical supplies through our industry-leading Interactive Response Technology (IRT) and expert consultancy.

The solutions offered by Almac Clinical Technologies facilitate more than simplifying patient and trial material management - they engineer quality into the clinical trial process. Our technology provides sponsors and CROs with the visibility and control needed to make data-driven decisions by leveraging advanced supply management functionality coupled with real-time site and patient data in a closed-loop environment.

Our expertise, energy and commitment have earned us a reputation as a trusted ally in the drug development process.



Commercial Services

We provide a wide range of customised commercial services from supporting product launch, manufacturing and/or packaging drug product, to securing supply chain with global serialisation solutions.

Almac Pharma Services' flexible, quality-led commercial solutions range from orphan drug launches to ongoing high volume commercial product manufacture, packaging and supply.



Product Sales, Marketing & Launch Services

Under the brand name Galen, we help our partner companies grow and expand into new markets through sales, marketing and launch excellence. In addition to our established market access we also offer expertise in medical affairs, pharmacovigilance and regulatory affairs.

We are positioned to distribute products across many global regions including the UK, the Republic of Ireland (ROI), the Nordics, Europe and the USA.

We pride ourselves on developing genuine relationships with our partners, crafting commercial strategy together and maintaining an open channel of communication as we manage their product to success.

Our partners share our commitment to advancing human health, and we work with them as one team with a common goal.



Our Global Expertise and Experience

- 5,600+ employees
- Over 50 years' experience
- 17 facilities
- Contributed to over 70% of FDA approved NME's (2015-2018)
- Work with all top 25 BioPharma companies
- Network of 60+ in-country depots for clinical supply



Our Locations

UK & Europe

Global HQ - Craigavon, Northern Ireland

EU HQ - Dundalk, Ireland

Belfast, Northern Ireland

Athlone, Ireland

Elvingston, Scotland

Charwood, England

Manchester, England

Gothenburg, Sweden

Copenhagen, Denmark

USA

US HQ - Souderton, PA

Audubon, PA

Lansdale, PA

San Francisco, CA

Durham, NC

Asia Pacific

Asia HQ - Singapore

Tokyo, Japan



*Late founder and chairman,
Sir Allen McClay*

The McClay Foundation

The McClay Foundation, which wholly owns the Almac Group, was founded by Sir Allen McClay and exists to make meaningful improvement and advancement in human health.

The McClay Foundation's objectives are:

1. To support and encourage research and innovation.
2. To advance the use of diagnostic tools and drugs in the prevention, control and cure of diseases.
3. To ensure latest advances in healthcare are available to all, including developing countries.
4. To generate and promote employment opportunities.
5. To support and promote such educational purposes as the trustees shall select, provided that such purposes shall be exclusively charitable in law.

The McClay Foundation's four strategic focus areas are:



Research and Development
of New Medicines



Oncology Research - Targets
and Biomarkers



Research led care for those in
end of life or life limited
circumstances



Promoting health & wellbeing
in disenfranchised
communities & geographical
locations